Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1261235 | PMC |
| http://dx.doi.org/10.1136/bmj.331.7522.966-b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chemotherapy induced phlebitis experienced by women with breast cancer following administration of epirubicin using a volumetric infusion pump: an observational study.
Eur J Oncol Nurs
June 2023
Velindre Cancer Centre, Velindre Road, Cardiff, CF14 2TL, UK. Electronic address:
Objective: To establish the incidence and severity of chemotherapy-induced phlebitis (CIP) following administration of epirubicin chemotherapy using a volumetric infusion pump (Hospira Plum 360), compared to a previous study of manual injection of epirubicin. Also the study aimed to gain insight into staff perceptions of ease of use and safety of infusion pump administration.
Methods: An observational study of women with breast cancer (n = 47) receiving epirubicin via volumetric infusion pump.
Leiomyosarcoma of the splenic vein with a history of bilateral retinoblastoma: A case report and review of the literature.
Mol Clin Oncol
February 2022
Department of Gastroenterology, Toranomon Hospital, Tokyo 105-8470, Japan.
Article Synopsis
- Diagnosing and treating leiomyosarcomas of the splenic vein is difficult, with no established treatment strategy for this rare condition.
- A case study details a 45-year-old woman who had surgery for a primary tumor in the splenic vein and later received targeted chemotherapy for metastatic lesions in her liver.
- Although the patient showed no recurrence after treatment, the rarity of this tumor highlights the need for more reports to develop effective clinical guidelines.
The successful treatment of 2 cases of portal vein tumor thrombus caused by hepatocellular carcinoma was reported. It is difficult to manage portal vein tumor thrombi by conventional transarterial chemoembolization(c-TACE)using lipiodol and a gelatin sponge. On the other hand, drug-eluting-microsphere TACE(DEM-TACE)can preserve hepatic function by maintaining the capillary circulation of sinusoids and the peribiliary arterial plexus.
View Article and Find Full Text PDFIdentifying Risk Factors for Anthracycline Chemotherapy-induced Phlebitis in Women with Breast Cancer: An Observational Study.
Clin Oncol (R Coll Radiol)
April 2021
Faculty of Life Sciences and Education, University of South Wales, Pontypridd, UK.
Aims: Anthracycline chemotherapy administered via a peripheral cannula results in severe anthracycline chemotherapy-induced phlebitis (ACIP) in about 20-30% of patients. Administering chemotherapy via a central venous catheter (CVC) prevents ACIP. However, CVCs are associated with an increased risk of thrombosis and sepsis.
View Article and Find Full Text PDFImaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
AJR Am J Roentgenol
October 2021
Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, 188 Shizi St, Suzhou 215006, China.
Drug-eluting bead transarterial chemoembolization (DEB-TACE) has emerged as an alternative to conventional TACE (cTACE) for treatment of hepatocellular carcinoma (HCC), although selection between the approaches remains controversial. The purpose of this study was to compare DEB-TACE and cTACE in the treatment of patients with unresectable HCC in terms of hepatobiliary changes on imaging and clinical complications. This retrospective study included 1002 patients (871 men, 131 women; mean age, 59 ± 12 years) from three centers who had previously untreated unresectable HCC and underwent DEB-TACE with epirubicin (780 procedures in 394 patients) or cTACE with ethiodized oil mixed with doxorubicin and oxaliplatin (1187 procedures in 608 patients) between May 2016 and November 2018.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!